Posted by Michael Wonder on 11 Mar 2021
FDA grants fast track designation to Spectrum Pharmaceuticals’ poziotinib
11 March 2021 - Spectrum Pharmaceuticals today announced that the U.S. FDA has granted fast track designation for poziotinib for the treatment of non-small cell lung cancer in previously treated patients with HER2 exon 20 mutations.
Spectrum plans to submit a new drug application for poziotinib later this year.
